Cosmetic Clinical Trials Can Explore Drug Effects Without IND – US FDA Proposed Rule
Executive Summary
The proposed rule addresses objections raised by industry in response to the agency’s former position set forth in 2013 guidance. The FDA now proposes two investigational new drug exemption pathways which it says will reduce regulatory burdens while ensuring that study subjects are protected.